Table 1. Clinical and demographic characteristics of kidney transplant patients.
| Characteristic | |
|---|---|
| Age (mean ± SD) | 54 ± 14 years (from 21 to 77 years) |
| Gender (male) (n (%)) | 61 (57.0%) |
| Time after transplantation (mean ± SD) | 7 ± 6 years (from 6 months to 26 years) |
| Induction with thymoglobulin, n = 116 (n (%)) | 11 (9.5%) |
| Number of immunosuppressive drugs (n (%)) | |
| 1 | 2 (1.6%) |
| 2 | 78 (60.9%) |
| 3 | 43 (33.6%) |
| 3 plus daratumumab/eculizumab/rituximab | 5 (3.9%) |
| Calcineurin inhibitor (n (%)) | 123 (96.1%) |
| Tacrolimus (n (% – of patients on calcineurin inhibitor)) | 110 (89.4%) |
| Cyclosporin (n (% – of patients on calcineurin inhibitor)) | 13 (10.6%) |
| Mycophenolic mofetil or sodium (n (%)) | 85 (66.4%) |
| Valganciclovir, n = 125 (n (%)) | 18 (14.4%) |
| Serum creatinine (mean ± SD) | 157 ± 89 µmol/L (from 51 to 503 µmol/L) |
| Estimated glomerular filtration rate (mean ± SD) | 48 ± 22 mL/min/1.73m2 (from 80 to 90 mL/min/1.73m2) |
| Frequent infections (n (%)) | 69 (53.9%) |
| History of malignant disease (n (%)) | 19 (14.8%) |
| History of rejection, percentage of all 107 patients (n (%)) | 17 (13.2%) |
| Patients with indication graft biopsy (n (%))* | 47 (36.7%) |
| History of rejection in patients with graft biopsy (n (%)) | 17 (36.2%) |
| Antibody-mediated rejection (n (% – of patients with biopsy)) | 14 (82.3%) |
| T cell-mediated rejection (n (% – of patients with biopsy)) | 2 (11.8%) |
| Mixed or borderline rejection (n (% – of patients with biopsy)) | 1 (5.9%) |
*Only clinically suspicious patients had graft biopsy. Unless otherwise stated, the number of samples was 128.